Evidence map›Paper›PMID 24737283›Full record

ArticleClinical rheumatology2014

Unmet need in Behcet's disease: most patients in routine follow-up continue to have oral ulcers.

Fatma Alibaz-Oner, Gonca Mumcu, Zeynep Kubilay, Gulsen Ozen, Gulce Celik, Aslı Karadeniz, Meryem Can, Sibel Yilmaz Oner, Nevsun Inanc, Pamir Atagunduz and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Management of Severe Behçet's Disease.Current rheumatology reports · 2026
    Review
  4. Article
  5. Update on the Diagnosis of Behçet's Disease.Diagnostics (Basel, Switzerland) · 2022
    Review
  6. Advances in the Treatment of Behcet's Disease.Current rheumatology reports · 2021
    Review
  7. Review
  8. Article
  9. Phenotypes in Behçet's syndrome.Internal and emergency medicine · 2019
    Review
  10. Review
  11. Article
  12. Behçet syndrome: a contemporary view.Nature reviews. Rheumatology · 2018
    Review
  13. Article
  14. Behçet's syndrome: providing integrated care.Journal of multidisciplinary healthcare · 2017
    Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Fatma Alibaz-OnerDivision of Rheumatology, School of Medicine, Marmara University, Istanbul, Turkey, falibaz@gmail.com.
Gonca Mumcu
Zeynep Kubilay
Gulsen Ozen
Gulce Celik
Aslı Karadeniz
Meryem Can
Sibel Yilmaz Oner
Nevsun Inanc
Pamir Atagunduz
Tulin Ergun
Haner Direskeneli
Marmara University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical course of Behcet's disease (BD) as a multisystemic disorder with a remitting-relapsing nature is insufficiently explored. As complete remission should be aimed in all inflammatory diseases, we investigated the frequency of complete remission in patients with BD followed in long-term, routine practice. In this retrospective study, 258 patients with BD who were regularly followed in outpatient clinics were assessed. The demographic and clinical data for active organ manifestations and treatment protocols were evaluated, and "complete remission" for this study was defined as no sign of any disease manifestation in the current visit and the preceding month. Two hundred fifty-eight patients with BD (F/M 130/128, mean age 41.1 ± 11.5 years) were included to the study. Mucocutaneous disease was present in 48.4 % (n = 125). Mean visit number was 6.8 ± 2.7, and mean follow-up duration was 45.8 ± 36.5 months. Patients were clinically active in 67.2 % (n = 1,182) of the total visits (n = 1,757), which increased to 75.6 % (68.1-90.3) when the month preceding the visit was also included. The most common active manifestation was oral ulcers (39.4-63.2 %) followed by other mucocutaneous manifestations and musculoskeletal involvement. When multivariate analysis was performed, oral ulcers, which are the main cause of the clinical activity, negatively correlated with immunosuppressive treatments (β = -0.356, p < 0.000) and age (β = -0.183, p = 0.04). It is fairly difficult to achieve complete remission in BD with current therapeutic regimens. The reluctance of the clinician to be aggressive for some BD manifestations with low morbidity, such as mucocutaneous lesions and arthritis, might be influencing the continuous, low-disease activity state, especially due to oral ulcers, in BD patients.

Indexed as

Administration, OralAdultBehcet SyndromeFemaleFollow-Up StudiesHumansImmunosuppressive AgentsInflammationMaleMiddle AgedMultivariate AnalysisOral UlcerQuality of LifeReferral and ConsultationRemission InductionRetrospective StudiesImmunosuppressive Agents

Identifiers

PMID24737283
OpenAlexW2064081517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.